.png){kind=logo}
We make every day a better day for people with diabetes.TM
MiniMed is an insulin delivery company advancing automated therapy for people with diabetes, today and tomorrow.
We believe technology should lift the burden of diabetes, so that every day is a better day.
The MiniMed Difference
For over 40 years, we've been a trusted partner in the diabetes community. Our innovation and support help people around the world do less work, and have more freedom.
Advanced insulin delivery
Our automated insulin delivery and smart dosing systems are designed to give more peace of mind and reduce diabetes burden.
Getting started, simplified
We make it easy to try new technology with an intuitive, guided experience that helps you start with confidence and ease.
Building the hands-free future
We're leading the way in building what's next, with a goal of providing technology that can handle diabetes management on its own.
More freedom every day
MiniMed systems are built on the same proven intelligence, giving you the freedom to manage in a way that fits your needs.
Guided by purpose.
Our leadership team is focused on shaping the future of diabetes care by advancing technologies
that make management more seamless and intuitive.
Changing lives is personal for us.
At MiniMed, diabetes isn’t abstract — it’s personal. Many of our employees have a direct connection to diabetes, bringing empathy and lived understanding to everything we create. That shared commitment drives us to show up every day with one purpose: making every day a better day for the people and families we serve.
Building better days, together.
The #MiniMedChampion global community is shaping a future where better days with diabetes are expected, and not the exception. MiniMed also partners with advocacy organizations worldwide to expand education, access, and possibility for millions of people.
Important Safety Information: MiniMed FlexTM system with SmartGuardTM technology with Simplera SyncTM sensor
The MiniMed FlexTM system is intended for the continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable rates for the management of type 1 diabetes mellitus in persons 7 years of age and older, and of type 2 diabetes mellitus in persons 18 years of age and older requiring insulin. The system is also intended to continuously monitor glucose values in the fluid under the skin. The MiniMed FlexTM system includes SmartGuardTM technology, which can be programmed to automatically adjust insulin delivery based on continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.
The Simplera SyncTM sensor can be used one time and has a life up to 6 days, followed by a grace period of 24 hours. During the grace period, the sensor will continue to work as it did during the first 6 days, to allow the patient to change their sensor more flexibly. However, some sensors may not survive the full wear period for a variety of reasons. Please be prepared to replace the sensor during the grace period to ensure sensor glucose values continue to be monitored.
The Simplera SyncTM sensor is not intended to be used directly to make therapy adjustments while the MiniMed FlexTM system is operating in manual mode. All therapy adjustments in Manual mode should be based on measurements obtained using a blood glucose meter and not on values provided by the Simplera SyncTM sensor. The Simplera SyncTM sensor has been studied and is approved for use in patients ages 7 years and older and in the arm insertion site only. Do not use the Simplera SyncTM sensor in the abdomen or other body sites, including the buttocks, due to unknown or different performance that could result in hypoglycemia or hyperglycemia.
The Medtronic MiniMed FlexTM System consists of the following devices: MiniMed FlexTM Insulin Pump and the Simplera SyncTM sensor. The system requires a prescription from a healthcare professional.
WARNING: Do not use the SmartGuardTM feature for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in the SmartGuardTM feature.
WARNING: Do not use the MiniMed FlexTM system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed FlexTM system.
WARNING: Do not use SG values to make treatment decisions, including delivering a bolus, while the pump is in Manual Mode. When the SmartGuardTM feature is active and you are no longer in Manual Mode, the pump uses an SG value, when available, to calculate a bolus amount. However, if your symptoms do not match the SG value, use a blood glucose (BG) meter to confirm the SG value. Failure to confirm glucose levels when your symptoms do not match the SG value can result in the infusion of too much or too little insulin, which may cause hypoglycemia or hyperglycemia.
Pump therapy is not recommended for people whose vision or hearing does not allow for the recognition of pump signals, alerts, or alarms. The safety of the MiniMed FlexTM system has not been studied in pregnant women or in persons using other anti-hyperglycemic therapies that do not include insulin. For complete details of the system, including user guides and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, see https://bit.ly/MiniMedRisks.
Important safety information: MiniMed Go system
The MiniMed Go system includes the MiniMed Go app, InPen smart insulin pen injector and either the Instinct continuous glucose monitoring (CGM) sensor or Simplera CGM sensor. The system is intended to aid in diabetes management through multiple daily injections of compatible rapid-acting insulins (Humalog, Novolog, or Fiasp). The app and system components each require a prescription. When used with Instinct CGM, the app is indicated for patients ages 7 years and older, or patients ages 2 to 6 years under the supervision of an adult caregiver. When used with Simplera CGM, the app is indicated for patients ages 18 and over. If using InPen alone, the app is intended for all ages, with patients under age 7 requiring supervision. Use of these systems requires, among other things, adequate hearing and vision, a compatible mobile device and operating system, an open app, adequate pairing and connectivity, proper setting, use of an approved rapid-acting insulin, mobile device battery power, proper settings, accurate manual logging of insulin doses administered by means other than InPen, and occasional blood glucose meter (BGM) readings. Establishment of settings and treatment decisions should be made in consultation with a healthcare professional and on the basis of a combination of glucose readings, trend arrows, glucose target, active alerts, and recent events (such as insulin doses, exercise, meals, and medications). Failure to observe these and other details as found in the user guides can result in incorrect dosing, missed alerts and notifications, and ultimately hypoglycemia or hyperglycemia, with serious injury or death possible. For additional safety information and user guides, see https://bit.ly/MiniMedRisks.